Explanipedia

Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphoma Open

Pierre Stéphan, Karan Chohan, Sairah Ahmed, Amrita Chauhan, Amy Ayers , et al. · 2025

Introduction Though transformed indolent lymphomas (tiNHL) have historically been associated with poor outcomes in the relapsed or refractory (R/R) setting, novel treatments e.g. chimeric antigen receptor (CAR) T-cells offer some improveme…

Real-world outcomes of mosunetuzumab use in indolent and aggressive lymphomas Open

Andrew Jallouk, Swetha Kambhampati, Shakthi Bhaskar, Narendranath Epperla, Steven M. Bair , et al. · 2025

Introduction Mosunetuzumab (mosun) is a CD20xCD3 bispecific antibody approved as a single agent for treatment of follicular lymphoma. It is also being studied in combination with other systemic therapies for aggressive B-cell lymphomas. He…

161 | OUTCOMES OF GLOFITAMAB AND EPCORITAMAB IN R/R DLBCL ELDERLY PATIENTS: A REAL‐WORLD EVIDENCE STUDY FROM THE CUBIC CONSORTIUM Open

Swetha Kambhampati, Liangyi Chen, Sairah Ahmed, Allison M. Bock, Narendranath Epperla , et al. · 2025

566 | REAL‐WORLD OUTCOMES OF MOSUNETUZUMAB USE FROM THE CUBIC CONSORTIUM Open

Andrew Jallouk, Lei Feng, Amy Ayers, Amrita Chauhan, Swetha Kambhampati , et al. · 2025

243 | REAL‐WORLD OUTCOMES OF CD20xCD3 BISPECIFIC ANTIBODY THERAPY IN ADULT PATIENTS WITH RELAPSED/REFRACTORY TRANSFORMED INDOLENT LYMPHOMA Open

P. Stéphan, Karan Chohan, Robert Redd, Saira Ahmed, Christopher R. Flowers , et al. · 2025

667 | REAL‐WORLD SAFETY AND EFFICACY OF EPCORITAMAB FOR PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMAS Open

Allison M. Bock, Lei Feng, Amy Ayers, Amrita Chauhan, Swetha Kambhampati , et al. · 2025

Feasibility of axicabtagene ciloleucel in the outpatient setting: primary analysis of prospective trial Open

Bhagirathbhai Dholaria, Shakthi Bhaskar, Vivek Patel, Eden Biltibo, Reena Jayani , et al. · 2025

The pivotal trials of axicabtagene ciloleucel (axi-cel) chimeric Antigen receptor (CAR-T) therapy and other CD19 CAR-Ts were mainly done in the inpatient setting. We conducted a single-center non-randomized open label prospective clinical …

Overview of approved CAR-T products and utility in clinical practice Open

Shakthi Bhaskar, Bhagirathbhai Dholaria, Bipin N. Savani, Salyka Sengsayadeth, Olalekan O. Oluwole · 2024

The Evolving Role of Bridging Therapy during CAR-T Therapy Open

Shakthi Bhaskar, Bhagirathbhai Dholaria, Bipin N. Savani, Olalekan O. Oluwole · 2024

Chimeric antigen receptor (CAR) T-cell therapy has gained wide used across an array of hematologic malignancies. Though CAR T therapy has changed outcomes in the treatment of many malignancies its administration can be complicated by delay…

Artificial intelligence modelling to assess the risk of cardiovascular disease in oncology patients Open

Samer S Al-Droubi, Eiman Jahangir, Karl M. Kochendorfer, Marianna Krive, Michal Laufer‐Perl , et al. · 2023

Aims There are no comprehensive machine learning (ML) tools used by oncologists to assist with risk identification and referrals to cardio-oncology. This study applies ML algorithms to identify oncology patients at risk for cardiovascular …

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome Open

Shakthi Bhaskar, Vivek Patel, David L. Porter, Stephen J. Schuster, Loretta J. Nastoupil , et al. · 2022

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of many patients with aggressive relapsed or refractory large B-cell lymphoma (LBCL). Treatment can be complicated by clinically evident cytokine release syndr…

Role of bridging therapy during chimeric antigen receptor T cell therapy Open

Shakthi Bhaskar, Bhagirathbhai Dholaria, Salyka Sengsayadeth, Bipin N. Savani, Olalekan O. Oluwole · 2021

Chimeric antigen receptor (CAR) T‐cell therapy has been approved for use in several relapsed/refractory hematologic malignancies and has significantly improved outcomes for these diseases. A number of different CAR T products are now being…

T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma Open

Paola Ghione, Promie Faruque, Neha Mehta‐Shah, Venkatraman Seshan, Neval Özkaya , et al. · 2020

Histone deacetylase inhibitors (HDACi) are active agents for peripheral T-cell lymphoma (PTCL). Anecdotally angioimmunoblastic T-cell lymphoma (AITL) appears to respond better than PTCL–not otherwise specified (NOS) to HDACi. The new World…

Lenalidomide demonstrates clinical activity in anaplastic lymphoma kinase-positive large B-cell lymphoma Open

Shakthi Bhaskar, Brooj Abro, Tyler J. Fraum, Neha Mehta‐Shah · 2020

Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+ LBCL) is known to be a rare and aggressive form of lymphoma that relapses quickly after both conventional chemotherapy and more targeted therapy. Lenalidomide is an immunomodu…

Shakthi Bhaskar YOU? Author Swipe